COPD Exacerbation Nursing Guide

AECOPD — Acute Exacerbation Definition

An AECOPD is an acute worsening of respiratory symptoms beyond normal daily variation that leads to a change in medication. It is the leading cause of COPD-related hospitalisation and death.

Precipitants

Respiratory infections: 70–80% — bacterial (H. influenzae, S. pneumoniae, M. catarrhalis) or viral (rhinovirus, influenza)
Air pollution — sand storms, smoke, industrial emissions (highly relevant in GCC)
Non-adherence to inhalers
PE, LVF, pneumothorax — exclude as differential
Inappropriate oxygen therapy (rare but important cause of deterioration)

AECOPD Severity Classification (GOLD)

Severity	Characteristics	Disposition
Mild	Managed with SABA increase alone; no healthcare visit required	Community management
Moderate	Requires SABA + SABD + systemic corticosteroids and/or antibiotics; hospital or ED visit	ED assessment; may discharge
Severe	Requires hospital admission	Inpatient
Very severe	ICU admission — ventilatory failure, haemodynamic instability	ICU / HDU

Indicators for Hospital Admission

Severe resting dyspnoea
Acute confusion, drowsiness (hypercapnic encephalopathy)
SpO₂ <90% or PaO₂ <6.0 kPa despite supplemental oxygen
pH <7.35 on ABG (ventilatory failure)
Tachypnoea >25/min despite treatment
Failure to respond to initial emergency treatment
Inadequate home support; inability to self-care

Controlled Oxygen Therapy — CRITICAL in COPD

HIGH-FLOW OXYGEN IS DANGEROUS IN COPD. Many COPD patients rely on hypoxic drive. Over-oxygenation (SpO₂ >92%) can suppress respiratory drive, worsen hypercapnia and cause respiratory arrest.

Target SpO₂ in AECOPD

Patient	Target SpO₂	Oxygen Delivery
COPD with known/suspected hypercapnia or type II respiratory failure	88–92%	Venturi mask 24–28% or nasal cannula 1–2 L/min
COPD without hypercapnia (confirmed by ABG)	88–92% initially until ABG confirms status	Venturi preferred for controlled delivery
COPD in cardiac arrest	100% — survival takes priority	Non-rebreather mask

Venturi mask colours (standard): 24% = blue, 28% = white, 31% = orange, 35% = yellow, 40% = red, 60% = green

ABG Interpretation in AECOPD

ABG Pattern	Interpretation	Action
pH <7.35, PaCO₂ ↑, HCO₃ normal/low	Acute type II (ventilatory) failure — decompensated	Consider NIV urgently
pH normal/>7.35, PaCO₂ ↑, HCO₃ ↑	Chronic type II failure — compensated (chronic retainer)	Controlled oxygen 88–92%; ABG-guided
pH >7.45, PaCO₂ ↓, PaO₂ ↓	Type I failure — hyperventilating, not retaining CO₂	Less restrictive oxygen; investigate precipitant

Treatment Bundles

Bronchodilators

SABA: Salbutamol 2.5 mg via nebuliser every 20–30 min for first hour, then every 1–4 hrs
SAMA: Ipratropium 500 mcg via nebuliser every 6 hrs — add to salbutamol for additive bronchodilation
Combination: Salbutamol + ipratropium together in same nebuliser cup — more effective than either alone
Driving gas: Air-driven nebuliser in COPD (not oxygen-driven — avoids uncontrolled oxygen delivery)
MDI + spacer: Equivalent to nebuliser in mild-moderate AECOPD — preferred if patient cooperative

Drive nebuliser with AIR not oxygen in COPD patients to avoid uncontrolled oxygen delivery.

Systemic Corticosteroids

Prednisolone 40 mg orally for 5 days — shortens recovery, reduces treatment failure
IV hydrocortisone 200 mg if unable to swallow or severe exacerbation
Longer courses offer NO additional benefit and increase side effects
Monitor blood glucose — steroids cause hyperglycaemia; critical in COPD patients with diabetes

Antibiotics

Indicated if: increased sputum volume AND purulence (green/yellow), fever, elevated CRP/procalcitonin
NOT required for all AECOPD — 50% are viral
Mild-moderate (outpatient): Amoxicillin 500 mg TDS × 5 days OR doxycycline 200 mg loading then 100 mg OD × 5 days
Hospital: Co-amoxiclav 1.2 g IV TDS OR levofloxacin 500 mg IV/PO OD if penicillin-allergic
Pseudomonal risk (frequent hospitalisations, recent antibiotics, structural lung disease): piperacillin-tazobactam or ceftazidime

Nursing Observations

Parameter	Frequency	Target
SpO₂	Continuous then hourly	88–92% in COPD
Respiratory rate	Every 1–2 hrs	Target <20/min; >25 = concerning
ABG	On admission; repeat 30–60 min after O₂ therapy change; 4-hourly if unstable	pH >7.35; PaCO₂ stable or improving
GCS / drowsiness	Every 1–2 hrs	Drowsiness = hypercapnic encephalopathy → NIV
Peak expiratory flow (PEF)	Before and after nebulisers	Objective bronchodilator response

Non-Invasive Ventilation (NIV)

NIV Indications in AECOPD

Primary indication: Acute hypercapnic respiratory failure with pH <7.35, PaCO₂ >6.5 kPa, not responding to medical therapy. NIV reduces intubation rate, ICU admission and mortality.

Criteria	Detail
pH	7.25–7.35 (moderate); <7.25 (severe — may require intubation)
PaCO₂	>6.5 kPa and rising despite treatment
Consciousness	Alert enough to protect airway and cooperate with mask
Contraindications	GCS <8 (unable to cooperate), facial trauma, recent upper GI surgery, copious secretions, haemodynamic instability (relative)

BiPAP Settings — Starting Parameters

Parameter	Starting Value	Titration
IPAP (inspiratory positive airway pressure)	10–15 cmH₂O	Increase by 2–4 cmH₂O every 30 min if CO₂ not improving; max 20–25 cmH₂O
EPAP (expiratory positive airway pressure)	4–5 cmH₂O	Increase to 6–8 if significant auto-PEEP or obstructive sleep apnoea
FiO₂ / flow	Titrate to SpO₂ 88–92%	Avoid over-oxygenation even on NIV
Back-up rate	10–12 breaths/min	To ensure ventilation during apnoeic periods

NIV Nursing Care

Mask fitting — correct size essential; common failure point. Check for air leak around mask
Skin protection — hydrocolloid dressing over nasal bridge to prevent pressure injury
ABG 1 hour after starting NIV — confirm response (pH improving, CO₂ falling)
Mouth care — NIV increases dry mouth; humidification circuit preferred
Aspiration risk — ensure patient not too drowsy; head of bed ≥30°
Frequent reassessment — if no improvement in 1–2 hrs → escalate to intubation vs palliation discussion

GCC-Specific Context

COPD in the GCC

Sandstorm particulates: PM10 and PM2.5 from shamal winds are major COPD exacerbation triggers — seasonal surge in AECOPD admissions during spring dust season
Biomass burning exposure: Particularly in rural Oman, Yemen-border Saudi Arabia — wood smoke inhalation causes COPD in non-smokers, especially women
Shisha (waterpipe) smoking: Highly prevalent in GCC youth and adults — causes COPD; one shisha session = ~100 cigarettes worth of smoke exposure. Shisha COPD is under-recognised in GCC primary care
Occupational exposure: Construction workers, petrochemical workers — silica, asbestos and chemical fume exposure causes occupational COPD
Poorly controlled asthma: Can progress to fixed obstruction (overlap syndrome — ACO) — common in GCC where asthma control is suboptimal

Exam Tips

SpO₂ target in COPD: 88–92% (NOT 94–98%) — classic exam trap
Venturi mask 24% = blue; delivers controlled, reliable FiO₂
Nebulise with AIR not oxygen in COPD
NIV for pH <7.35 + raised CO₂ not responding to treatment
Prednisolone 40 mg OD × 5 days — not longer
Drowsiness/confusion = hypercapnic encephalopathy → consider NIV urgently

Exam MCQs — DHA / SCFHS / QCHP

Q1. A nurse is caring for a patient with AECOPD. SpO₂ is 87%. The nurse applies a non-rebreather mask at 15 L/min. SpO₂ rises to 99%. What is the PROBLEM with this action?

A) No problem — SpO₂ 99% is excellent for all patients B) Over-oxygenation in COPD suppresses hypoxic drive, causes CO₂ retention and may cause respiratory arrest C) A non-rebreather mask is too expensive for routine COPD management D) SpO₂ should be maintained above 95% in COPD patients

✅ B — Target SpO₂ in COPD is 88–92%. Over-oxygenation eliminates the hypoxic drive in chronic CO₂ retainers, worsens hypercapnia and can cause respiratory depression and arrest. Use a Venturi mask (24–28%) for controlled delivery.

Q2. A COPD patient's ABG shows: pH 7.28, PaCO₂ 8.9 kPa, PaO₂ 7.1 kPa, HCO₃ 28 mmol/L, on controlled oxygen via 28% Venturi mask. What is the NEXT step?

A) Increase oxygen to 60% Venturi mask to improve PaO₂ B) Initiate non-invasive ventilation (BiPAP) C) Administer IV bicarbonate to correct pH D) Repeat ABG in 4 hours before taking action

✅ B — pH <7.35 with rising CO₂ despite medical treatment = indication for NIV (BiPAP). Increasing oxygen worsens CO₂ retention. IV bicarbonate does not treat the underlying ventilatory failure. Delay risks further deterioration and need for intubation.

Q3. A nurse is about to nebulise salbutamol for a COPD patient. Which driving gas should be used?

A) Oxygen at 8 L/min — better bronchodilator effect B) Air at 6–8 L/min C) Either oxygen or air — makes no difference D) Heliox mixture for better aerosol delivery

✅ B — Drive COPD nebulisers with air, NOT oxygen. Using oxygen as the driving gas delivers uncontrolled high-flow O₂ alongside the bronchodilator, bypassing the carefully titrated Venturi mask and risking CO₂ retention.

Q4. A COPD patient on NIV becomes drowsy, stops cooperating and appears unable to protect their airway. What is the CORRECT action?

A) Increase BiPAP IPAP pressure and continue NIV B) Remove mask and reassess — patient may be improving C) Call the intensive care team urgently — patient may require endotracheal intubation D) Administer doxapram IV to stimulate respiratory drive

✅ C — NIV failure (inability to protect airway, worsening consciousness on NIV) requires urgent escalation to the ICU team. The patient may need endotracheal intubation and invasive mechanical ventilation. Continuing NIV in a patient who cannot protect their airway risks aspiration and respiratory arrest.

🫁 Acute COPD Exacerbation